Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia

被引:0
作者
Ching-Hon Pui
机构
[1] St. Jude Children’s Research Hospital,Departments of Oncology and Pathology
[2] the University of Tennessee Health Science Center,undefined
来源
Frontiers of Medicine | 2015年 / 9卷
关键词
acute lymphoblastic leukemia; genomics; pharmacogenetics; pharmacogenomics;
D O I
暂无
中图分类号
学科分类号
摘要
With the cure rate of childhood acute lymphoblastic leukemia (ALL) approaching 90%, further improvement in the treatment outcome and quality of life of patients will require better understanding of the mechanisms of drug resistance, identifying new leukemic cell genetic lesions that are amendable to available target therapy, and optimizing treatment based on host pharmacodynamics and pharmacogenomics. Deeper characterization of leukemic cell genetic abnormalities has discovered new subtypes of leukemia such as early T-cell precursor ALL and Philadelphia chromosome-like ALL, and identified many genomic alterations that have diagnostic, prognostic, or therapeutic implications. In this regard, several novel fusion transcripts are responsive to ABL tyrosine kinase inhibitors and potentially to JAK inhibitors. Genome-wide analyses have also unraveled the role of inherited cancer predisposing genes and small nucleotide polymorphisms of several genes in the development of childhood ALL. These advances promise to lead to more sophisticated personalized treatment strategies in the near future.
引用
收藏
页码:1 / 9
页数:8
相关论文
共 1076 条
[1]  
Pui CH(2013)A 50-year journey to cure childhood acute lymphoblastic leukemia Semin Hematol 50 185-196
[2]  
Evans WE(2012)Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120 1165-1174
[3]  
Pui CH(2013)Genome sequencing of lymphoid malignancies Blood 122 3899-3907
[4]  
Mullighan CG(2013)Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy Hematology (Am Soc Hematol Educ Program) 2013 126-130
[5]  
Evans WE(2009)Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia Lancet Oncol 10 147-156
[6]  
Relling MV(2012)The genetic basis of early T-cell precursor acute lymphoblastic leukaemia Nature 481 157-163
[7]  
Mullighan CG(2009)Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia N Engl J Med 360 470-480
[8]  
Relling MV(2009)A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genomewide classification study Lancet Oncol 10 125-134
[9]  
Ramsey LB(2013)Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with Bcell precursor ALL Blood 122 2622-2629
[10]  
Coustan-Smith E(2013)Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children’s Oncology Group TARGET Project Blood 121 485-488